Kahalalide F vs Mambalgin-1
Head-to-head comparison of Kahalalide F (Kahalalide F) and Mambalgin-1 (Mambalgin-1 from Dendroaspis polylepis venom) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Kahalalide F | Mambalgin-1 |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Kahalalide F | Mambalgin-1 from Dendroaspis polylepis venom |
| Molecular Weight | 1111.3 Da | 6,300 Da |
| Half-Life | N/A | Minutes to hours |
| Amino Acids | N/A | 57 |
| Typical Dose | 0.1-3 mg/m2 IV in early trials | 0.1-1 nmol intrathecal|10-100 nM in vitro|single-dose rodent studies |
| Route | Intravenous | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 55 |
| Research Status | Pre-clinical | Pre-clinical |
Kahalalide F Benefits
- ✓antineoplastic
- ✓pro-apoptotic
- ✓membrane-active
- ✓anti-proliferative
Mambalgin-1 Benefits
- ✓ASIC channel inhibition
- ✓non-opioid analgesia research
- ✓sensory-neuron physiology
- ✓lead optimization for pain therapeutics
Kahalalide F Dosing
IV infusion in phase I oncology studies|dose escalation used in trials|preclinical nanomolar assays
Mambalgin-1 Dosing
Intrathecal pain-behavior studies|ASIC1a/ASIC1b electrophysiology|Acute dosing in rodents
Kahalalide F Side Effects
- ⚠fatigue
- ⚠nausea
- ⚠transaminase elevation
Mambalgin-1 Side Effects
- ⚠Hypoactivity at high dose
- ⚠off-target ASIC blockade
- ⚠local irritation
Research Overview
Kahalalide F
Kahalalide F was investigated in multiple preclinical and early clinical cancer studies because of its unusual membrane-disrupting and anti-tumor effects. Development highlighted the promise and limits of marine depsipeptides as oncology leads.
Mambalgin-1
Pre-clinical work shows mambalgin-1 can reduce pain behaviors by modulating proton-gated ion channels in peripheral and central pathways. It has become an important template for developing ASIC-targeted analgesics.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.